Shanghai Institute of Materia Medica of the Chinese Academy of Sciences has identified G-protein coupled receptor 84 (GPR84) antagonists reported to be useful for the treatment of multiple sclerosis, inflammatory bowel disease, fibrosis, neurodegenerative disease and arthritis.
Eternygen UK Ltd. has disclosed 5,6,7,8-tetrahydro-2,6- and 2,7-naphthyridine derivatives acting as sodium-coupled citrate transporter 5 (SLC13A5) inhibitors reported to be useful for the treatment of eating disorders, liver cancer, neurodegeneration, and liver and metabolic diseases.
Korea Research Institute of Chemical Technology (KRICT) has synthesized novel pyrimidine-2,4-diamine derivatives acting as EGFR (HER1; erbB1) and/or HER2 (erbB2) (mutant) inhibitors reported to be useful for the treatment of cancer.
Immunomolecular Therapeutics Inc. has described compounds targeting HLA-DQ2 reported to be useful for the treatment of type 1 diabetes, myasthenia gravis, Stiff-man syndrome, Addison and celiac diseases.
Prelude Therapeutics Inc. has divulged proteolysis-targeting chimeric (PROTAC) compounds comprising a Von Hippel-Lindau E3 ubiquitin ligase (VHL)-binding moiety covalently linked to a SMARCA2- or SMARCA4-targeting moiety through a linker reported to be useful for the treatment of cancer.
Otsuka Pharmaceutical Co. Ltd. has synthesized hydrogenated quinoxalines acting as serotonin and/or norepinephrine and/or dopamine reuptake inhibitors reported to be useful for the treatment of attention deficit hyperactivity disorder (ADHD).